在过去的十年中，器官样品因其在器官发生、疾病建模和药物筛选等方面的应用而备受欢迎，从而推动了新疗法的发展。目前，这种培养方法已经被用于重建肾脏、肝脏、大脑和胰脏等器官的复杂构成和功能。不过，培养环境和细胞状态等各种细节因素的不同也会导致器官样品的差异，特别是在药物定量等方面。通过高级的生物打印技术，标准化可以被实现。该技术可以在所需位置打印出各种细胞和生物材料，同时可以制造出复杂的三维生物结构。因此，生物打印技术除了可以使器官样品更加标准化以外，还可以促进生产自动化和更加贴近真实器官的生产过程。此外，人工智能（AI）也已经成为质量监督和控制的有效工具。因此，器官样品、生物打印技术和人工智能可以结合使用，以获得高质量的多个应用的体外模型。

In the last decade, organoids have gained popularity for developing mini-organs to support advancements in the study of organogenesis, disease modeling, and drug screening and, subsequently, in the development of new therapies. To date, such cultures have been used to replicate the composition and functionality of organs such as the kidney, liver, brain, and pancreas. However, depending on the experimenter, the culture environment and cell conditions may slightly vary, resulting in different organoids; this factor significantly affects their application in new drug development, especially during quantification. Standardization in this context can be achieved using bioprinting technology-an advanced technology that can print various cells and biomaterials at desired locations. This technology offers numerous advantages, including the manufacturing of complex three-dimensional biological structures. Therefore, in addition to the standardization of organoids, bioprinting technology in organoid engineering can facilitate automation in the fabrication process as well as a closer mimicry of native organs. Further, artificial intelligence (AI) has currently emerged as an effective tool to monitor and control the quality of final developed objects. Thus, organoids, bioprinting technology, and AI can be combined to obtain high-quality in vitro models for multiple applications.